Mina Sooch

Mina Sooch, is a biotech entrepreneur and investor with a track record of founding and leading multiple clinical-stage biopharmaceutical companies. She served as CEO and President of Ocuphire (now Opus Genetics), Gemphire (now Metavia), and ProNAi Therapeutics—each transitioned from private to Nasdaq-listed firms. She also co-founded Afmedica and Nephrion (now SeaStar Medical), and has led Apjohn Ventures since 2003.

In 2024, she launched PremTara Ventures to advise biotech companies and previously managed Tara Ventures I, an angel fund. Earlier, she held roles at North Coast Technology Investors and Monitor Deloitte. Sooch currently serves on the board of Priority Health and has held board roles at Ocuphire, Gemphire, ProNAi, Biovie, ZyStor, and others. She holds a B.S. in Chemical Engineering from Wayne State University and an M.B.A. from Harvard Business School.

Nil

Below is a list of company engagements where the filer has filed a Schedule 13D and/or engaged in a proxy campaign. As the filer does not file a Form 13F, current ownership information is not available.